Survival after primary surgery compared with neoadjuvant chemotherapy in early-stage ovarian cancer

Abstract

Objectives: Our study evaluates survival of women with early-stage ovarian cancer treated with neoadjuvant chemotherapy (NAC) vs primary debulking surgery (PDS). Methods: We used the 2004-2015 NCDB to identify women with early ovarian cancer treated with multiagent chemotherapy and appropriate surgery. Logistic regression was used to identify predictors of NAC. Overall survival estimates were compared using Kaplan-Meier analysis and Cox proportional hazards regression models were used to examine variables. Results: In total, 14,627 women were included. The majority (96%) underwent PDS while (4%) underwent NAC. Median survival times were 40 months (95% CI [37.190-47.280], P Download : Download high-res image (124KB) Download : Download full-size image Conclusions: Women treated with neoadjuvant chemotherapy (NAC) had worse overall and 5-year survival. This finding agrees with the accepted convention of reserving NAC for women with advanced, unresectable disease.